Quarterly ResultOct 27, 2026, 08:01 AM
CTS Corp Q3 Sales Up 5% to $149.6M; Raises 2026 Guidance
AI Summary
CTS Corporation announced strong third-quarter 2026 results, with sales up 5% year-over-year to $149.6 million and net income rising to $17.8 million, or $0.61 per diluted share. The company also raised its full-year 2026 guidance for both sales and adjusted diluted earnings per share. The acquisition of Millar was highlighted as a key strategic move to further diversify the company's portfolio, especially within the medical sector.
Key Highlights
- CTS Corporation reported Q3 2026 sales of $149.6 million, a 5% increase year-over-year.
- Net income for Q3 2026 was $17.8 million, or $0.61 per diluted share, up from $13.7 million, or $0.46 per diluted share in Q3 2025.
- Adjusted gross margin improved to 42.2% from 38.9% in Q3 2025.
- Adjusted EBITDA margin increased to 24.7% from 23.8% in Q3 2025.
- The company raised its 2026 guidance for sales to $580-$590 million and adjusted diluted EPS to $2.78-$2.88.
- Sales to diversified end-markets grew 7% and now represent 60% of total sales.
- The acquisition of Millar is expected to advance diversification, particularly in the medical end market.
Price Impact
More from CTS
Business Update1d ago, 1:31 PM
CTS Corp Investor Presentation Discloses Strategy, Acquisition, and Guidance
Quarterly ResultJul 28, 2:16 PM
CTS Q2 Net Sales $144.8M, Net Earnings $19.2M, Diluted EPS $0.66
Business UpdateJul 28, 8:08 AM
CTS Corp Investor Update: LTM Revenue $564M, FY26 EPS Guidance $2.55-$2.70